Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Recce Pharmaceuticals Ltd. ( (AU:RCE) ).
Recce Pharmaceuticals Ltd has commenced patient dosing in a Phase 3 clinical trial for diabetic foot infections in Indonesia, aiming to enroll up to 310 patients. This trial is significant due to Indonesia’s high diabetes prevalence and the urgent need for new treatment solutions. The company’s RECCE® 327 Topical Gel has shown high efficacy against antibiotic-resistant pathogens, highlighting its potential impact on the treatment of chronic wounds and positioning Recce as a key player in addressing global health challenges.
The most recent analyst rating on (AU:RCE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a leading developer in the pharmaceutical industry, specializing in a new class of synthetic anti-infectives. The company focuses on creating innovative treatments for infections, with a significant emphasis on addressing antibiotic-resistant pathogens. Their market focus includes diabetic foot infections and other diabetes-related infections, leveraging opportunities in regions with high diabetes prevalence like Indonesia.
Average Trading Volume: 131,944
Technical Sentiment Signal: Hold
Current Market Cap: A$118.6M
See more data about RCE stock on TipRanks’ Stock Analysis page.